DICE Therapeutics
Oliver Yasbek, CPA has a diverse and extensive work experience. Oliver is currently serving as the VP of Finance at DICE Therapeutics since January 2022. Prior to that, they worked as the Senior Director of Financial Planning and Analysis at Adamas Pharmaceuticals, Inc. from April 2021 to December 2021. Oliver also held the position of Senior Director of Finance and Accounting at Custopharm, Inc. from July 2019 to April 2021.
Before joining Custopharm, Inc., Oliver Yasbek worked at Nixon as the Senior Director of Finance and Accounting from April 2019 to July 2019. Oliver also served as the Corporate Controller at Nixon from March 2016 to April 2019. Prior to Nixon, they held leadership positions at Digirad, where they worked as the Vice President of Finance and Corporate Controller from January 2015 to March 2016, and as the Corporate Controller from January 2013 to December 2014.
Oliver Yasbek started their career at Sapphire Energy Inc., where they served as the Corporate Controller from September 2012 to January 2013. Prior to that, they held the position of Senior Manager of Accounting and Finance from April 2012 to August 2012, and Manager of Accounting and Finance from November 2010 to March 2012.
Oliver Yasbek began their professional journey at PwC, where they worked as a Manager of Assurance from July 2010 to October 2010. Before that, they held the role of Senior Associate from September 2007 to June 2010, and Associate from September 2004 to August 2007.
Oliver Yasbek, CPA, obtained a Bachelor of Science (BS) degree in Accounting from the University of Maryland - Robert H. Smith School of Business. Oliver attended this institution from 2000 to 2004.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.